Project Grant R44AI188778
Award Date 8/13/26
Completion Date 1/31/28
Dollars Obligated $300K
Federal Agency
Awardee
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Seattle, WA 98122, USA
Similar Awards
- The National Institute of Arthritis and Musculoskeletal and Skin Diseases awarded Virtici LLC $306,341 on August 26, 2026, under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846) to develop VTC-B35, a bioengineered oral probiotic therapy for rheumatoid arthritis. The award funds commercialization of VTC-B35, designed to induce long-term disease remission in rheumatoid arthritis patients by stimulating regulatory T cells and B cells to produce immune tolerance rather...
- The National Institute of Allergy and Infectious Diseases awarded the University of Florida $607,599 on September 1, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to develop a hybrid biomaterial immunotherapy system for rheumatoid arthritis. The funded work centers on engineering and testing REGVAK, a novel hybrid polymeric microparticle–lipid nanoparticle system designed to address the root cause of rheumatoid arthritis by targeting dendritic cell activation...
- The National Institute of Allergy and Infectious Diseases awarded Washington State University $497,779 on February 17, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to investigate the role of the FN-14 receptor in TNF-induced inflammation and tissue destruction, with performance through January 31, 2031. The research addresses the partial ineffectiveness of TNF-alpha inhibitors in treating rheumatoid arthritis and related inflammatory diseases in over 40...
- The National Institute of Allergy and Infectious Diseases awarded $267,000 to the Benaroya Research Institute at Virginia Mason on June 11, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855). The award funds research into circulating and mucosal immune cell populations affected by therapeutic interleukin-23 blockade in Crohn's disease patients treated with risankizumab. The project will quantify and characterize TH17 cells, mucosa-associated invariant T cells,...
- The National Institute of Allergy and Infectious Diseases awarded Biotherapeutics, Inc. $314,363 on September 1, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to develop oral first-in-class small-molecule therapeutics targeting a novel immunometabolic pathway for multiple sclerosis treatment. Biotherapeutics, Inc., a clinical-stage biotechnology company headquartered in Blacksburg, Virginia, will conduct Phase I research validating the safety, efficacy, and...
- The National Institute of Allergy and Infectious Diseases awarded Cedars-Sinai Medical Center $740,319 on June 10, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to investigate TH17 plasticity in rheumatoid arthritis. The research explores the conversion of interleukin-17A-producing TH17 cells into pathogenic IL17A-negative cell populations (exTH17) within the synovial joints of rheumatoid arthritis patients. Despite targeted IL-17A therapy, many RA patients...
- The National Institute of Allergy and Infectious Diseases awarded Seattle Children's Hospital $911,271 on August 4, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to investigate mechanisms regulating integration of engineered B cells in intestinal immunity and inflammation. The research aims to develop a B cell-based immunotherapy platform for treatment of inflammatory bowel disease and related immune-mediated diseases. The project focuses on long-lived plasma...
- This $600,000 project grant from the National Institute of Allergy and Infectious Diseases will support General Nanotherapeutics LLC's development of nanoimmunotherapy for chronic immune-mediated diseases. The company will leverage nanoparticles to target and expand immunoregulatory cells ex vivo and assess their ability to suppress effector immune responses and induce remission in vivo, including in a lupus model. This proof-of-concept work aligns with the Allergy and Infectious Diseases...
- The National Institute of Allergy and Infectious Diseases (NIAID), part of the Department of Health and Human Services, awarded $306,810 to Capture Bioscience Inc. on July 22, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) for development and validation of a high-throughput autoimmune antibody detection platform. Capture Bioscience will adapt its Beads by Time-of-Flight (B-TOF) technology to create a comprehensive autoimmunity panel capable of simultaneously...
- The National Institute of Allergy and Infectious Diseases awarded Biotherapeutics, Inc. $314,363 on August 13, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to develop novel oral immunoregulatory therapeutics for Helicobacter pylori–induced bacterial gastritis. Biotherapeutics, Inc., a clinical-stage biotechnology company headquartered in Blacksburg, Virginia, will evaluate the therapeutic efficacy of a host-centered product candidate in regulating local and...